Trial Profile
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2405319 With 28 Days of Subcutaneous Injections in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2405319 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 11 Jun 2013 New trial record